TIMBER PHARMACEUTICALS INC (TMBR) Stock Price, Quote, News and Overview
NYSEARCA:TMBR - NYSE Arca - US8870802084 - Common Stock - Currency: USD
TMBR Quote, Performance and Key Statistics
0.3426
+0 (+0.74%)
The current stock price of TMBR is 0.3426 USD. In the past month the price decreased by -87.33%. In the past year, price decreased by -77.61%.
TMBR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About TMBR
Company Profile
Timber Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases. The company is headquartered in Warren, New Jersey and currently employs 9 full-time employees. The company went IPO on 2015-06-11. The firm is focused on the development and commercialization of treatments for orphan dermatologic diseases. The firm is also focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis (CI), including X-linked recessive CI (XLRI) and autosomal recessive CI (ARCI) and other sclerotic skin diseases. Its lead late-stage program is TMB-001. TMB-003 is its earliest stage program. TMB-001 is a topical formulation of isotretinoin using its patented IPEG delivery system, completed its Phase IIb clinical trial for the treatment of moderate to severe subtypes of CI. The earliest stage product in its pipeline is TMB-003, a formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist. The company is in preclinical development as a locally applied formulation for the treatment of sclerotic skin diseases.
Company Info
TIMBER PHARMACEUTICALS INC
3 Mountainview Road, Suite 100
WARREN NEW JERSEY 07920 US
CEO: John Koconis
Employees: 9
Company Website: https://www.timberpharma.com/
Phone: 19176973130.0
TIMBER PHARMACEUTICALS INC / TMBR FAQ
What is the stock price of TIMBER PHARMACEUTICALS INC today?
The current stock price of TMBR is 0.3426 USD. The price increased by 0.74% in the last trading session.
What is the ticker symbol for TIMBER PHARMACEUTICALS INC stock?
The exchange symbol of TIMBER PHARMACEUTICALS INC is TMBR and it is listed on the NYSE Arca exchange.
On which exchange is TMBR stock listed?
TMBR stock is listed on the NYSE Arca exchange.
What is the price forecast or stock price prediction for TIMBER PHARMACEUTICALS INC stock?
6 analysts have analysed TMBR and the average price target is 11.22 USD. This implies a price increase of 3174.96% is expected in the next year compared to the current price of 0.3426. Check the TIMBER PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TIMBER PHARMACEUTICALS INC worth?
TIMBER PHARMACEUTICALS INC (TMBR) has a market capitalization of 1.04M USD. This makes TMBR a Nano Cap stock.
How many employees does TIMBER PHARMACEUTICALS INC have?
TIMBER PHARMACEUTICALS INC (TMBR) currently has 9 employees.
Is TIMBER PHARMACEUTICALS INC (TMBR) expected to grow?
The Revenue of TIMBER PHARMACEUTICALS INC (TMBR) is expected to decline by -100% in the next year. Check the estimates tab for more information on the TMBR EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy TIMBER PHARMACEUTICALS INC (TMBR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TMBR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TMBR, evaluating the profitability, health, valuation and growth aspects
- TIMBER PHARMACEUTICALS INC (TMBR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TIMBER PHARMACEUTICALS INC (TMBR) Sales and EPS estimates to see what analysts future expectations are.
- TIMBER PHARMACEUTICALS INC (TMBR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TIMBER PHARMACEUTICALS INC (TMBR) Insider and Institutional Ownership to learn about the owners and their transactions.
- TIMBER PHARMACEUTICALS INC (TMBR) Stock Chart to make your own analysis
- TIMBER PHARMACEUTICALS INC (TMBR) Latest news and press-releases to stay up to date.
Does TIMBER PHARMACEUTICALS INC (TMBR) stock pay dividends?
TMBR does not pay a dividend.
When does TIMBER PHARMACEUTICALS INC (TMBR) report earnings?
TIMBER PHARMACEUTICALS INC (TMBR) will report earnings on 2024-03-29, after the market close.
What is the Price/Earnings (PE) ratio of TIMBER PHARMACEUTICALS INC (TMBR)?
TIMBER PHARMACEUTICALS INC (TMBR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.88).
TMBR Technical Analysis
TMBR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TMBR. While TMBR seems to be doing ok healthwise, there are quite some concerns on its profitability.
TMBR Financial Highlights
Over the last trailing twelve months TMBR reported a non-GAAP Earnings per Share(EPS) of -5.88. The EPS increased by 58.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -116.71% | ||
| ROE | -195.55% | ||
| Debt/Equity | 0 |
TMBR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to TMBR. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of -2636.84% and a revenue growth -100% for TMBR